Because several studies show an association between P-gp transporter overexpression and treatment-resistant depression [147], [18F]MC225 has received AIFA approval to begin an additional Phase II clinical trial investigating the correlation between P-gp and depression, and patient recruitment is currently ongoing. This evidence concerns the gene PGP and major depressive disorder.